company background image
8279

Syngen BiotechLtd TPEX:8279 Stock Report

Last Price

NT$154.00

Market Cap

NT$4.2b

7D

16.7%

1Y

69.2%

Updated

13 Aug, 2022

Data

Company Financials
8279 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends2/6

8279 Stock Overview

Syngen Biotech Co., Ltd. operates as a biotech company in Taiwan.

Syngen BiotechLtd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Syngen BiotechLtd
Historical stock prices
Current Share PriceNT$154.00
52 Week HighNT$155.00
52 Week LowNT$83.50
Beta0.80
1 Month Change23.20%
3 Month Change23.20%
1 Year Change69.23%
3 Year Change12.00%
5 Year Change22.31%
Change since IPO1,461.29%

Recent News & Updates

Shareholder Returns

8279TW PharmaceuticalsTW Market
7D16.7%3.2%1.7%
1Y69.2%6.8%-9.8%

Return vs Industry: 8279 exceeded the TW Pharmaceuticals industry which returned 6.8% over the past year.

Return vs Market: 8279 exceeded the TW Market which returned -9.8% over the past year.

Price Volatility

Is 8279's price volatile compared to industry and market?
8279 volatility
8279 Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement5.0%
10% most volatile stocks in TW Market8.4%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 8279 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 8279's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/aWei Ren Chenhttps://www.syngen.com.tw

Syngen Biotech Co., Ltd. operates as a biotech company in Taiwan. The company manufactures and sells active pharmaceutical ingredients, including Mupirocin, an antibiotic against gram-positive bacteria that is used for the topical treatment of superficial infections, such as impetigo and infections, as well as to control infected eczema, wounds, and burns; and nutraceutical ingredients comprising probiotics, medicinal fungi, and entomogenous fungi. It also offers biology fermentation, biology agriculture and aquaculture, and functional food products.

Syngen BiotechLtd Fundamentals Summary

How do Syngen BiotechLtd's earnings and revenue compare to its market cap?
8279 fundamental statistics
Market CapNT$4.17b
Earnings (TTM)NT$296.39m
Revenue (TTM)NT$1.66b

14.1x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
8279 income statement (TTM)
RevenueNT$1.66b
Cost of RevenueNT$1.05b
Gross ProfitNT$601.69m
Other ExpensesNT$305.30m
EarningsNT$296.39m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)10.94
Gross Margin36.35%
Net Profit Margin17.91%
Debt/Equity Ratio23.5%

How did 8279 perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

37%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 8279 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8279?

Other financial metrics that can be useful for relative valuation.

8279 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.8x
Enterprise Value/EBITDA11.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 8279's PE Ratio compare to its peers?

8279 PE Ratio vs Peers
The above table shows the PE ratio for 8279 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.3x
1752 Nang Kuang Pharmaceutical
17.5xn/aNT$3.7b
1777 SYN-TECH Chem. & Pharm
20.5x32.4%NT$2.7b
4120 Orient EuroPharma
61.1xn/aNT$2.9b
1762 Chunghwa Chemical Synthesis & Biotech
10.1x8.7%NT$4.3b
8279 Syngen BiotechLtd
14.1xn/aNT$4.2b

Price-To-Earnings vs Peers: 8279 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the peer average (27.3x).


Price to Earnings Ratio vs Industry

How does 8279's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 8279 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the TW Pharmaceuticals industry average (20.5x)


Price to Earnings Ratio vs Fair Ratio

What is 8279's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8279 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8279's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 8279 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8279 (NT$154) is trading above our estimate of fair value (NT$103.31)

Significantly Below Fair Value: 8279 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Syngen BiotechLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


47.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Syngen BiotechLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Syngen BiotechLtd performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 8279 has a high level of non-cash earnings.

Growing Profit Margin: 8279's current net profit margins (17.9%) are higher than last year (14.9%).


Past Earnings Growth Analysis

Earnings Trend: 8279's earnings have grown by 15.7% per year over the past 5 years.

Accelerating Growth: 8279's earnings growth over the past year (45.8%) exceeds its 5-year average (15.7% per year).

Earnings vs Industry: 8279 earnings growth over the past year (45.8%) exceeded the Pharmaceuticals industry 4.2%.


Return on Equity

High ROE: 8279's Return on Equity (16.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Syngen BiotechLtd's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 8279's short term assets (NT$1.2B) exceed its short term liabilities (NT$1.0B).

Long Term Liabilities: 8279's short term assets (NT$1.2B) exceed its long term liabilities (NT$230.2M).


Debt to Equity History and Analysis

Debt Level: 8279's net debt to equity ratio (11.1%) is considered satisfactory.

Reducing Debt: 8279's debt to equity ratio has increased from 20.5% to 23.5% over the past 5 years.

Debt Coverage: 8279's debt is well covered by operating cash flow (64.9%).

Interest Coverage: 8279's interest payments on its debt are well covered by EBIT (130.4x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Syngen BiotechLtd current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


2.60%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 8279's dividend (2.6%) is higher than the bottom 25% of dividend payers in the TW market (2.49%).

High Dividend: 8279's dividend (2.6%) is low compared to the top 25% of dividend payers in the TW market (6.52%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 8279 has been paying a dividend for less than 10 years.

Growing Dividend: 8279's dividend payments have increased, but the company has only paid a dividend for 6 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (36.6%), 8279's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: 8279 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.2yrs

Average board tenure


CEO

Wei Ren Chen

17.08yrs

Tenure

Wei Ren Chen has been Chairman of the Board and President of Syngen Biotech Co., Ltd. since March 15, 1999 and July 1, 2005 respectively. Wei Ren Chen is employed by Taiwan Drug Relief Foundation.Wei Ren...


Board Members

Experienced Board: 8279's board of directors are considered experienced (9.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Syngen Biotech Co.,Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Syngen Biotech Co.,Ltd.
  • Ticker: 8279
  • Exchange: TPEX
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$4.174b
  • Shares outstanding: 27.10m
  • Website: https://www.syngen.com.tw

Number of Employees


Location

  • Syngen Biotech Co.,Ltd.
  • No.154, Kaiyuan Road
  • Sinying District
  • Tainan City
  • 73055
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/13 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.